Dexpramipexole
- Generic Name
- Dexpramipexole
- Drug Type
- Small Molecule
- Chemical Formula
- C10H17N3S
- CAS Number
- 104632-28-2
- Unique Ingredient Identifier
- WI638GUS96
- Background
Dexpramipexole is under investigation in clinical trial NCT01511029 (Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)).
Areteia Therapeutics Advances Oral Dexpramipexole for Eosinophilic Asthma in Phase III Trials
• Areteia Therapeutics is progressing dexpramipexole, a novel oral therapy, into Phase III clinical trials for severe eosinophilic asthma.
• Dexpramipexole aims to reduce eosinophil levels by inhibiting their maturation in the bone marrow, offering a potential alternative to injectable biologics.
• Akero Therapeutics will present updates on its MASH treatment, EFX, currently in Phase 3 trials, at the J.P. Morgan Healthcare Conference.
• Both Areteia and Akero will present at the J.P. Morgan Healthcare Conference on January 14, 2025, to discuss their clinical-stage programs.
Critical Treatment Gap Persists for T2-Low Asthma Despite Therapeutic Advances
• T2-low asthma remains significantly underdiagnosed and undertreated due to the absence of reliable biomarkers, creating a stark contrast to the therapeutic advances seen in T2-high asthma.
• Several pharmaceutical companies, including Areteia Therapeutics and AstraZeneca, are exploring novel treatment approaches, with dexpramipexole and Breztri showing potential for addressing T2-low asthma.
• Current diagnostic challenges, treatment adherence issues, and the lack of targeted biological therapies highlight the urgent need for improved diagnostic tools and therapeutic options for T2-low asthma patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath